Qiagen N.V. (NYSE: QGEN) Stock Competitors & Peer Comparison
See QGEN's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for QGEN and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| QGEN | $44.18 | -0.85% | 9.1B | 18.25 | $2.42 | +5.99% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.64% |
| TMO | $675.00 | -0.50% | 249.1B | 29.09 | $23.16 | +0.27% |
| DHR | $224.49 | +0.32% | 157.8B | 28.14 | $7.98 | +0.64% |
| NTRA | $412.56 | +0.92% | 59.1B | -312.55 | -$1.32 | N/A |
| A | $172.79 | -0.03% | 48.8B | 29.74 | $5.81 | +0.59% |
| IQV | $270.37 | -1.69% | 44.4B | 22.24 | $12.13 | N/A |
| WAT | $433.54 | +0.75% | 42.6B | 31.71 | $13.68 | N/A |
| IDXX | $519.26 | +1.14% | 41B | 36.52 | $14.22 | N/A |
| ILMN | $270.00 | -1.42% | 40.9B | 53.68 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
QGEN vs DHR-PB Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, QGEN's ROE is +0.12%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, QGEN is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
QGEN vs TMO Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, TMO has a market cap of 249.1B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while TMO trades at $675.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas TMO's P/E ratio is 29.09. In terms of profitability, QGEN's ROE is +0.12%, compared to TMO's ROE of +0.13%. Regarding short-term risk, QGEN is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
QGEN vs DHR Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, DHR has a market cap of 157.8B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while DHR trades at $224.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas DHR's P/E ratio is 28.14. In terms of profitability, QGEN's ROE is +0.12%, compared to DHR's ROE of +0.08%. Regarding short-term risk, QGEN is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
QGEN vs NTRA Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, NTRA has a market cap of 59.1B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while NTRA trades at $412.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas NTRA's P/E ratio is -312.55. In terms of profitability, QGEN's ROE is +0.12%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, QGEN is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
QGEN vs A Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, A has a market cap of 48.8B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while A trades at $172.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas A's P/E ratio is 29.74. In terms of profitability, QGEN's ROE is +0.12%, compared to A's ROE of +0.20%. Regarding short-term risk, QGEN is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
QGEN vs IQV Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while IQV trades at $270.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas IQV's P/E ratio is 22.24. In terms of profitability, QGEN's ROE is +0.12%, compared to IQV's ROE of +0.22%. Regarding short-term risk, QGEN is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check IQV's competition here
Waters Corporation (NYSE: WAT)
QGEN vs WAT Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, WAT has a market cap of 42.6B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while WAT trades at $433.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas WAT's P/E ratio is 31.71. In terms of profitability, QGEN's ROE is +0.12%, compared to WAT's ROE of +0.02%. Regarding short-term risk, QGEN is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
QGEN vs IDXX Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, IDXX has a market cap of 41B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while IDXX trades at $519.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas IDXX's P/E ratio is 36.52. In terms of profitability, QGEN's ROE is +0.12%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, QGEN is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
QGEN vs ILMN Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, ILMN has a market cap of 40.9B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while ILMN trades at $270.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas ILMN's P/E ratio is 53.68. In terms of profitability, QGEN's ROE is +0.12%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, QGEN is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
QGEN vs MTD Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, MTD has a market cap of 30.5B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while MTD trades at $1,511.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas MTD's P/E ratio is 34.73. In terms of profitability, QGEN's ROE is +0.12%, compared to MTD's ROE of -12.00%. Regarding short-term risk, QGEN is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
QGEN vs DGX Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, DGX has a market cap of 26.1B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while DGX trades at $236.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas DGX's P/E ratio is 23.30. In terms of profitability, QGEN's ROE is +0.12%, compared to DGX's ROE of +0.14%. Regarding short-term risk, QGEN is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
QGEN vs LH Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while LH trades at $309.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas LH's P/E ratio is 18.37. In terms of profitability, QGEN's ROE is +0.12%, compared to LH's ROE of +0.12%. Regarding short-term risk, QGEN is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
QGEN vs GH Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, GH has a market cap of 23.7B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while GH trades at $177.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas GH's P/E ratio is -50.56. In terms of profitability, QGEN's ROE is +0.12%, compared to GH's ROE of +2.11%. Regarding short-term risk, QGEN is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
QGEN vs EXAS Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas EXAS's P/E ratio is -95.37. In terms of profitability, QGEN's ROE is +0.12%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, QGEN is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
QGEN vs MEDP Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while MEDP trades at $618.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas MEDP's P/E ratio is 36.28. In terms of profitability, QGEN's ROE is +0.12%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, QGEN is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
QGEN vs ILMNV Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas ILMNV's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.12%, compared to ILMNV's ROE of N/A. Regarding short-term risk, QGEN is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
QGEN vs RVTY Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, RVTY has a market cap of 16.9B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while RVTY trades at $151.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas RVTY's P/E ratio is 28.24. In terms of profitability, QGEN's ROE is +0.12%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, QGEN is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
QGEN vs PKI Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas PKI's P/E ratio is 41.45. In terms of profitability, QGEN's ROE is +0.12%, compared to PKI's ROE of +0.03%. Regarding short-term risk, QGEN is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
QGEN vs CRL Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CRL has a market cap of 14.1B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CRL trades at $292.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CRL's P/E ratio is 29.61. In terms of profitability, QGEN's ROE is +0.12%, compared to CRL's ROE of -0.08%. Regarding short-term risk, QGEN is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
QGEN vs ICLR Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while ICLR trades at $172.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas ICLR's P/E ratio is 14.06. In terms of profitability, QGEN's ROE is +0.12%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, QGEN is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check ICLR's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
QGEN vs BLLN Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, BLLN has a market cap of 5.7B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while BLLN trades at $123.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas BLLN's P/E ratio is 175.83. In terms of profitability, QGEN's ROE is +0.12%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, QGEN is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check BLLN's competition here
RadNet, Inc. (NASDAQ: RDNT)
QGEN vs RDNT Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while RDNT trades at $70.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas RDNT's P/E ratio is 153.89. In terms of profitability, QGEN's ROE is +0.12%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, QGEN is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
QGEN vs GRAL Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while GRAL trades at $126.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas GRAL's P/E ratio is -12.83. In terms of profitability, QGEN's ROE is +0.12%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, QGEN is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check GRAL's competition here
Sotera Health Company (NASDAQ: SHC)
QGEN vs SHC Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, SHC has a market cap of 5.2B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while SHC trades at $18.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas SHC's P/E ratio is 19.10. In terms of profitability, QGEN's ROE is +0.12%, compared to SHC's ROE of +0.27%. Regarding short-term risk, QGEN is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
QGEN vs SYNH Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas SYNH's P/E ratio is 61.40. In terms of profitability, QGEN's ROE is +0.12%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, QGEN is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
QGEN vs VCYT Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while VCYT trades at $45.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas VCYT's P/E ratio is 22.72. In terms of profitability, QGEN's ROE is +0.12%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, QGEN is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
QGEN vs CDNA Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CDNA trades at $63.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CDNA's P/E ratio is 75.81. In terms of profitability, QGEN's ROE is +0.12%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, QGEN is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
QGEN vs OLK Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas OLK's P/E ratio is -96.59. In terms of profitability, QGEN's ROE is +0.12%, compared to OLK's ROE of -0.07%. Regarding short-term risk, QGEN is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
QGEN vs WGS Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while WGS trades at $88.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas WGS's P/E ratio is 245.56. In terms of profitability, QGEN's ROE is +0.12%, compared to WGS's ROE of -0.39%. Regarding short-term risk, QGEN is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
QGEN vs PSNL Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, PSNL has a market cap of 1.8B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while PSNL trades at $16.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas PSNL's P/E ratio is -15.10. In terms of profitability, QGEN's ROE is +0.12%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, QGEN is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
QGEN vs OPK Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas OPK's P/E ratio is -6.07. In terms of profitability, QGEN's ROE is +0.12%, compared to OPK's ROE of -0.06%. Regarding short-term risk, QGEN is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
QGEN vs CSTL Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CSTL trades at $35.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CSTL's P/E ratio is -54.26. In terms of profitability, QGEN's ROE is +0.12%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, QGEN is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
QGEN vs FLGT Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, FLGT has a market cap of 630.5M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while FLGT trades at $22.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas FLGT's P/E ratio is 2220.00. In terms of profitability, QGEN's ROE is +0.12%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, QGEN is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
QGEN vs GRALV Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas GRALV's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.12%, compared to GRALV's ROE of N/A. Regarding short-term risk, QGEN is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
QGEN vs NEO Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, NEO has a market cap of 496.7M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while NEO trades at $19.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas NEO's P/E ratio is 148.69. In terms of profitability, QGEN's ROE is +0.12%, compared to NEO's ROE of -0.06%. Regarding short-term risk, QGEN is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
QGEN vs CO Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CO's P/E ratio is 5.06. In terms of profitability, QGEN's ROE is +0.12%, compared to CO's ROE of +0.11%. Regarding short-term risk, QGEN is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
QGEN vs MYGN Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, MYGN has a market cap of 393.8M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while MYGN trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas MYGN's P/E ratio is -32.08. In terms of profitability, QGEN's ROE is +0.12%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, QGEN is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
QGEN vs FLDM Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas FLDM's P/E ratio is -4.74. In terms of profitability, QGEN's ROE is +0.12%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, QGEN is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
QGEN vs BDSX Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, BDSX has a market cap of 236.9M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while BDSX trades at $29.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas BDSX's P/E ratio is -9.18. In terms of profitability, QGEN's ROE is +0.12%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, QGEN is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
QGEN vs XGN Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, XGN has a market cap of 210.7M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while XGN trades at $8.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas XGN's P/E ratio is -10.77. In terms of profitability, QGEN's ROE is +0.12%, compared to XGN's ROE of -1.22%. Regarding short-term risk, QGEN is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
QGEN vs FRNM Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, FRNM has a market cap of 130.4M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while FRNM trades at $15.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas FRNM's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.12%, compared to FRNM's ROE of N/A. Regarding short-term risk, QGEN is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
QGEN vs GTH Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas GTH's P/E ratio is -1.11. In terms of profitability, QGEN's ROE is +0.12%, compared to GTH's ROE of -1.01%. Regarding short-term risk, QGEN is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check GTH's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
QGEN vs IMDX Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, IMDX has a market cap of 126.6M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while IMDX trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas IMDX's P/E ratio is -2.63. In terms of profitability, QGEN's ROE is +0.12%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, QGEN is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check IMDX's competition here
Genetic Technologies Limited (NASDAQ: GENE)
QGEN vs GENE Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas GENE's P/E ratio is -38.25. In terms of profitability, QGEN's ROE is +0.12%, compared to GENE's ROE of -1.85%. Regarding short-term risk, QGEN is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
QGEN vs SERA Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, SERA has a market cap of 77.9M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while SERA trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas SERA's P/E ratio is -3.14. In terms of profitability, QGEN's ROE is +0.12%, compared to SERA's ROE of -0.47%. Regarding short-term risk, QGEN is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
QGEN vs PRPO Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, PRPO has a market cap of 42.2M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while PRPO trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas PRPO's P/E ratio is -36.38. In terms of profitability, QGEN's ROE is +0.12%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, QGEN is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
QGEN vs QUCY Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, QUCY has a market cap of 31.4M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while QUCY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas QUCY's P/E ratio is -0.06. In terms of profitability, QGEN's ROE is +0.12%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, QGEN is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
QGEN vs MDXH Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, MDXH has a market cap of 29M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while MDXH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas MDXH's P/E ratio is -0.77. In terms of profitability, QGEN's ROE is +0.12%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, QGEN is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
QGEN vs AKU Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas AKU's P/E ratio is -0.13. In terms of profitability, QGEN's ROE is +0.12%, compared to AKU's ROE of -5.32%. Regarding short-term risk, QGEN is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
QGEN vs BNR Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, BNR has a market cap of 19.7M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while BNR trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas BNR's P/E ratio is -21.38. In terms of profitability, QGEN's ROE is +0.12%, compared to BNR's ROE of -0.13%. Regarding short-term risk, QGEN is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
QGEN vs CEMI Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CEMI's P/E ratio is -0.63. In terms of profitability, QGEN's ROE is +0.12%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, QGEN is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
QGEN vs ENZ Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas ENZ's P/E ratio is -2.24. In terms of profitability, QGEN's ROE is +0.12%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, QGEN is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
QGEN vs PMD Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas PMD's P/E ratio is -5.24. In terms of profitability, QGEN's ROE is +0.12%, compared to PMD's ROE of -0.32%. Regarding short-term risk, QGEN is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
QGEN vs ME Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas ME's P/E ratio is -0.03. In terms of profitability, QGEN's ROE is +0.12%, compared to ME's ROE of -42.03%. Regarding short-term risk, QGEN is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
QGEN vs MYNZ Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, QGEN's ROE is +0.12%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, QGEN is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
QGEN vs CHEK Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CHEK's P/E ratio is -0.43. In terms of profitability, QGEN's ROE is +0.12%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, QGEN is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
QGEN vs BIAFW Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, BIAFW has a market cap of 9.6M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while BIAFW trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas BIAFW's P/E ratio is 1.02. In terms of profitability, QGEN's ROE is +0.12%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, QGEN is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
QGEN vs CNTG Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CNTG's P/E ratio is -0.23. In terms of profitability, QGEN's ROE is +0.12%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, QGEN is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
QGEN vs ADVB Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, ADVB has a market cap of 8.8M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while ADVB trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas ADVB's P/E ratio is -58.00. In terms of profitability, QGEN's ROE is +0.12%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, QGEN is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
QGEN vs NDRA Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, NDRA has a market cap of 7.7M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas NDRA's P/E ratio is -0.90. In terms of profitability, QGEN's ROE is +0.12%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, QGEN is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
QGEN vs APDN Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas APDN's P/E ratio is -0.10. In terms of profitability, QGEN's ROE is +0.12%, compared to APDN's ROE of -7.23%. Regarding short-term risk, QGEN is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
QGEN vs NVTA Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas NVTA's P/E ratio is -0.00. In terms of profitability, QGEN's ROE is +0.12%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, QGEN is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
QGEN vs LMDX Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas LMDX's P/E ratio is -0.01. In terms of profitability, QGEN's ROE is +0.12%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, QGEN is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
QGEN vs LMDXW Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, QGEN's ROE is +0.12%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, QGEN is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
QGEN vs BIAF Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while BIAF trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas BIAF's P/E ratio is -0.93. In terms of profitability, QGEN's ROE is +0.12%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, QGEN is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
QGEN vs DMTK Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas DMTK's P/E ratio is -0.04. In terms of profitability, QGEN's ROE is +0.12%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, QGEN is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
QGEN vs NOTV Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas NOTV's P/E ratio is -0.03. In terms of profitability, QGEN's ROE is +0.12%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, QGEN is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
QGEN vs SQL Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas SQL's P/E ratio is -0.40. In terms of profitability, QGEN's ROE is +0.12%, compared to SQL's ROE of -30.46%. Regarding short-term risk, QGEN is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
QGEN vs AWH Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas AWH's P/E ratio is -0.09. In terms of profitability, QGEN's ROE is +0.12%, compared to AWH's ROE of +1.62%. Regarding short-term risk, QGEN is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
QGEN vs HTGM Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas HTGM's P/E ratio is -0.03. In terms of profitability, QGEN's ROE is +0.12%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, QGEN is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
QGEN vs BIOC Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas BIOC's P/E ratio is -0.01. In terms of profitability, QGEN's ROE is +0.12%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, QGEN is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
QGEN vs SQLLW Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, QGEN's ROE is +0.12%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, QGEN is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
QGEN vs ISPC Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, ISPC has a market cap of 175K. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while ISPC trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas ISPC's P/E ratio is -0.04. In terms of profitability, QGEN's ROE is +0.12%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, QGEN is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
QGEN vs WGSWW Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, QGEN's ROE is +0.12%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, QGEN is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check WGSWW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
QGEN vs PRXL Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas PRXL's P/E ratio is 42.97. In terms of profitability, QGEN's ROE is +0.12%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, QGEN is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for QGEN.Check PRXL's competition here
Danaher Corporation (NYSE: DHR-PA)
QGEN vs DHR-PA Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, QGEN's ROE is +0.12%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, QGEN is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check DHR-PA's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
QGEN vs OCDX Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas OCDX's P/E ratio is -42.28. In terms of profitability, QGEN's ROE is +0.12%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, QGEN is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check OCDX's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
QGEN vs NDRAW Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas NDRAW's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.12%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, QGEN is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check NDRAW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
QGEN vs MEUSW Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas MEUSW's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.12%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, QGEN is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
QGEN vs BNGOW Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas BNGOW's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.12%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, QGEN is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
QGEN vs CHEKZ Comparison September 2026
Qiagen N.V. (NYSE: QGEN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QGEN stands at 9.1B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, QGEN is priced at $44.18 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QGEN currently has a P/E ratio of 18.25, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, QGEN's ROE is +0.12%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, QGEN is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for QGEN.Check CHEKZ's competition here